References
- Thestrup-Pedersen K. Adverse reactions in the skin from anti-hypertensive drugs. Dan Med Bull 1987;34:3–5
- Steckelings UM, Artuc M, Wollschläger T, et al. Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. Acta Derm Venereol 2001;81:321–325
- Atzori L, Pinna AL, Ferreli C, Aste N. Pityriasis rosea-like adverse reaction: review of the literature and experience of an Italian drug-surveillance center. Dermatol Online J 2006;12:1
- Litt JZ. Litt’s drug eruption reference manual including drug interaction. 14th ed. London: Informa Healthcare; 2008
- Vena GA, Cassano N. Toxic drug-induced chronic pruritus. Immunopharmacol Immunotoxicol 2012;34:1075–1076
- Wilkin JK, Hammond JJ, Kirkendall WM. The captopril-induced eruption. A possible mechanism: cutaneous kinin potentiation. Arch Dermatol 1980;116:902–905
- Wilkin JK, Kirkendall WM. Pityriasis rosea-like rash from captopril. Arch Dermatol 1982;118:186–187
- Chalmers D, Whitehead A, Lawson DH. Postmarketing surveillance of captopril for hypertension. Br J Clin Pharmacol 1992;34:215–223
- Gambini D, Sala F, Gianotti R, Cusini M. Exanthematous reaction to irbesartan. J Eur Acad Dermatol Venereol 2003;17:472–473
- Pfab F, Athanasiadis GI, Kollmar A, et al. Lichenoid drug eruption due to an antihypertonic drug containing irbesartan and hydrochlorothiazide. Allergy 2006;61:786–787
- Ozturk G, Turk BG, Senturk B, et al. Exanthematous drug eruption due to valsartan. Cutan Ocul Toxicol 2013;32:41–45
- Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation 2005;111:315–320
- Landmesser U, Drexler H. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. J Hypertens 2006;24:S39–S43
- Battegay EJ, de Miguel LS, Petrimpol M, Humar R. Effects of anti-hypertensive drugs on vessel rarefaction. Curr Opin Pharmacol 2007;7:151–157
- Steckelings UM, Wollschläger T, Peters J, et al. Human skin: source of and target organ for angiotensin II. Exp Dermatol 2004;13:148–154